Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.0007
Schlusskurs vom Vortag:
$0.0007
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.49M
KGV:
0.00
EPS:
-1.7861
Netto-Cashflow:
$-7.62M
1W Leistung:
-100.00%
1M Leistung:
-57.01%
6M Leistung:
-93.93%
1J Leistung:
-85.81%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.0007
Paxmedica Inc Stock (PXMD) Company Profile
Compare PXMD vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PXMD
Paxmedica Inc
|
0.00 | 0 | 0 | -13.49M | -7.62M | -1.7861 |
VRTX
Vertex Pharmaceuticals Inc
|
437.02 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.00 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
698.47 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.17 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
153.13 | 31.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Paxmedica Inc Aktie (PXMD) Neueste Nachrichten
Strategic Execution in Focus for Paxmedica Investors - AD HOC NEWS
ProMetic Life Sciences (OTCMKTS:PFSCF) & PaxMedica (NASDAQ:PXMD) Financial Contrast - Defense World
Comparing PaxMedica (NASDAQ:PXMD) & ProMetic Life Sciences (OTCMKTS:PFSCF) - Defense World
Paxmedica’s PAX-101 Under the Microscope: Pipeline Progress and FDA Milestones - AD HOC NEWS
MorphoSys (NASDAQ:MOR) vs. PaxMedica (NASDAQ:PXMD) Head to Head Comparison - Defense World
Autism Spectrum Disorder Market to Reach USD 4.07 Billion - GlobeNewswire
PXMD Stock Institutional Owners - Quiver Quantitative
Plus Therapeutics Regains Compliance With Two Nasdaq Listing Rules - marketscreener.com
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
PaxMedica Renames to Kuvatris, Cancels Shares - TipRanks
PaxMedica announces board resignations amid transition - Investing.com
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data - ACCESS Newswire
PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - ACCESS Newswire
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc. - ACCESS Newswire
PaxMedica, Inc. (PXMD) Stock Price, News, Quote & History - Yahoo
PaxMedica Secures Groundbreaking China Patent for Autism Treatment Breakthrough After 100 Years - Stock Titan
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection - finance.yahoo.com
Autism Spectrum Disorder Therapeutics Market size is set to grow by USD 766.1 million from 2024-2028, Increasing prevalence of asd to boost the market growth, Technavio - PR Newswire
PaxMedica (PXMD) Stock Trends and Sentiment 2025 - MarketBeat
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Ensuring Access to Life-Saving Treatments - FinancialContent
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 - finance.yahoo.com
Cardio Diagnostics Holdings, Inc. (CDIO) stock price, news, quote and history - Yahoo! Finance Singapore
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy - Yahoo Finance
PXMD Stock Price and Chart — OTC:PXMD - TradingView
PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - GlobeNewswire
As Autism Cases Rise, Biopharma Springs Into Action - BioSpace
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness - Yahoo Finance
Why Is PaxMedica (PXMD) Stock Up 93% Today? - InvestorPlace
PaxMedica Achieves Key Milestone in the Development of - GlobeNewswire
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - GlobeNewswire
PaxMedica (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals with ASD - The Globe and Mail
Ocean Biomedical, Inc. (OCEA) options chain - Yahoo! Finance Singapore
HC Wainwright & Co. Initiates Coverage of PaxMedica (PXMD) with Buy Recommendation - Nasdaq
PaxMedica (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M - The Globe and Mail
PaxMedica prices stock and warrant offering at $1.30 per unit - Investing.com UK
PaxMedica, Inc. (PXMD) latest stock news and headlines - Yahoo Finance UK
PaxMedica News of FDA Type-B Meeting Shared in Audio Broadcast - Yahoo Finance
Why Is PaxMedica (PXMD) Stock Down 40% Today? - TradingView — Track All Markets
Virax Biolabs Group Limited (VRAX) stock price, news, quote and history - Yahoo! Finance Singapore
PaxMedica progresses with PAX-101 for sleeping sickness By Investing.com - Investing.com UK
PaxMedica Surges After Publication Of Statistically Significant Data From Its Autism Spectrum Study - Nasdaq
PaxMedica buys research assets to support PAX-101 FDA application (PXMD) - Seeking Alpha
PaxMedica Announces 1-for-17 Reverse Stock Split - GlobeNewswire
PaxMedica (NASDAQ: PXMD) Reports on Low-Dose Suramin for ASD Research - Digital Journal
PaxMedica stock soars 110% on FDA update for lead drug PAX-101 (PXMD) - Seeking Alpha
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD) - Yahoo Finance
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023 - Yahoo Finance
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301 - Yahoo Finance
PaxMedica Comments on Common Stock Volatility - Yahoo Finance
PaxMedica CEO Interviewed by The BRAIN Foundation - Yahoo Finance
PaxMedica seeks SAHPRA approval to initiate ASD therapy trial - clinicaltrialsarena.com
Finanzdaten der Paxmedica Inc-Aktie (PXMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.91%
0.19%
Kapitalisierung:
|
Volumen (24h):